Structure Therapeutics Inc. - American Depositary Shares (NQ:GPCR)

66.84 +0.29 (+0.44%)

Streaming Delayed Price Updated: 10:11 AM EST, Feb 23, 2026 Add to My Watchlist

Price and Volume

Volume	138,547
Open	67.78
Bid (Size)	66.60 (500)
Ask (Size)	67.08 (100)
Prev. Close	66.55
Today's Range	66.50 - 68.26
52wk Range	13.22 - 94.90
Shares Outstanding	N/A
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

The Trillion-Dollar Pharmaceutical Giant: Eli Lilly Makes History as Weight-Loss Revolution Drives Unprecedented Growth

February 17, 2026

In a historic moment for the global healthcare industry, Eli Lilly and Company (NYSE:LLY) has officially cemented its position as the world’s first pharmaceutical company to surpass a $1 trillion...

Via MarketMinute

Structure Therapeutics Stock Up 187% in One Year as Fund Trims $8 Million From Stake ↗

February 17, 2026

Structure Therapeutics develops oral therapies for chronic diseases, using a proprietary platform to target G-protein-coupled receptors.

Via The Motley Fool

Performance

YTD	-1.9%	-1.9%
1 Month	-26.0%	-26.0%
3 Month	+89.3%	+89.3%
6 Month	+259.9%	+259.9%
1 Year	+217.8%	+217.8%

More News

Eli Lilly Projects Record $80B-$83B Revenue for 2026 as Metabolic Franchise Decouples from Competition

February 06, 2026

Via MarketMinute

VKTX, TERN, GPCR Shares Rally As Novo Nordisk Sounds Willingness Towards Portfolio-Expansion Deals ↗

January 14, 2026

Via Stocktwits

This Healthcare Company Believes Its GLP-1 Pill Could Be "Next in Line" After Novo Nordisk and Eli Lilly. Its Valuation Is a Fraction of Theirs. ↗

February 05, 2026

Via The Motley Fool

A 10% Owner Of Structure Therapeutics Shed Shares ↗

January 13, 2026

Via The Motley Fool

Can This Stock Double Again in 2026? ↗

January 11, 2026

Via The Motley Fool

The 2026 Pharma M&A Outlook: Obesity, HIV, and the Biotech Renaissance

January 07, 2026

Via MarketMinute

Why Did Structure Therapeutics Stock Surge Pre-Market Today? ↗

December 08, 2025

Via Stocktwits

Hims & Hers Enters 2026 On Solid Ground — Stock Rises Even After Novo Nordisk Leaves It Off Wegovy Partner List ↗

January 05, 2026

Via Stocktwits

Biotech’s Resurgence: How a Year-End Rally and M&A Frenzy Set the Stage for 2026

December 31, 2025

Via MarketMinute

The Case for Small-Cap Diversification: Why Investors are Looking Beyond Mega-Cap Tech

December 23, 2025

Via MarketMinute

Novo Nordisk Breaks the Mold: Oral Obesity Breakthrough Sends Shares to New Heights as Pharma Landscape Shifts

December 23, 2025

Via MarketMinute

The Great Rotation: Small-Caps Seize the Spotlight as Mega-Cap Fatigue Sets In

December 22, 2025

Via MarketMinute

The Great Rotation: Small-Cap Growth Surges as Investors Ditch Defensive Safety for Post-Fed Gains

December 18, 2025

Via MarketMinute

The Great Rotation: Small-Caps Break Out as Russell 2000 Hits Record Highs in Late 2025

December 18, 2025

Via MarketMinute

Structure Therapeutics Announces Initiation of Phase 1 Clinical Study of Oral Small Molecule Amylin Receptor Agonist ACCG-2671 for the Treatment of Obesity

December 17, 2025

From Structure Therapeutics Inc.

Via GlobeNewswire

Structure Therapeutics Announces Closing of Upsized $747.5 Million Public Offering of ADSs and Pre-Funded Warrants and Full Exercise of the Underwriters’ Option to Purchase Additional ADSs

December 11, 2025

From Structure Therapeutics Inc.

Via GlobeNewswire

Structure Therapeutics Announces Pricing of Upsized $650 Million Public Offering of ADSs and Pre-Funded Warrants

December 09, 2025

From Structure Therapeutics Inc.

Via GlobeNewswire

Why Structure Therapeutics Stock Doubled and Then Some on Monday ↗

December 08, 2025

Via The Motley Fool

Global Markets Brace for Fed Decision Amidst Divergent Policies and Geopolitical Crosscurrents

December 09, 2025

Via MarketMinute

Structure Therapeutics Announces Proposed $500 Million Public Offering of American Depositary Shares and Pre-Funded Warrants

December 08, 2025

From Structure Therapeutics Inc.

Via GlobeNewswire

What's going on in today's session ↗

December 08, 2025

Via Chartmill

Wondering what's happening in today's pre-market session? ↗

December 08, 2025

Via Chartmill

Structure Therapeutics Reports Positive Topline Data from ACCESS Program for its Once-Daily Oral Small Molecule GLP-1 Receptor Agonist, Aleniglipron

December 08, 2025

From Structure Therapeutics Inc.

Via GlobeNewswire

Frequently Asked Questions

Is Structure Therapeutics Inc. - American Depositary Shares publicly traded?

Yes, Structure Therapeutics Inc. - American Depositary Shares is publicly traded.

What exchange does Structure Therapeutics Inc. - American Depositary Shares trade on?

Structure Therapeutics Inc. - American Depositary Shares trades on the Nasdaq Stock Market

What is the ticker symbol for Structure Therapeutics Inc. - American Depositary Shares?

The ticker symbol for Structure Therapeutics Inc. - American Depositary Shares is GPCR on the Nasdaq Stock Market

What is the current price of Structure Therapeutics Inc. - American Depositary Shares?

The current price of Structure Therapeutics Inc. - American Depositary Shares is 66.84

When was Structure Therapeutics Inc. - American Depositary Shares last traded?

The last trade of Structure Therapeutics Inc. - American Depositary Shares was at 02/23/26 10:11 AM ET

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.